WallStSmart

Biofrontera Inc (BFRI)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 31816% more annual revenue ($14.74B vs $46.17M). VTRS leads profitability with a -2.8% profit margin vs -13.8%. VTRS earns a higher WallStSmart Score of 48/100 (D+).

BFRI

Avoid

35

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.0Quality: 3.5
Piotroski: 3/9Altman Z: -5.37

VTRS

Hold

48

out of 100

Grade: D+

Growth: 2.7Profit: 3.5Value: 4.3Quality: 5.0
Piotroski: 4/9Altman Z: 0.55
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BFRI.

VTRSSignificantly Overvalued (-85.0%)

Margin of Safety

-85.0%

Fair Value

$8.72

Current Price

$16.51

$7.79 premium

UndervaluedFair: $8.72Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BFRI1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
32.9%10/10

Revenue surging 32.9% year-over-year

VTRS1 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Areas to Watch

BFRI4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$23.02M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.263/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

VTRS4 concerns · Avg: 2.5/10
Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Return on EquityProfitability
-2.9%2/10

ROE of -2.9% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.552/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BFRI

The strongest argument for BFRI centers on Revenue Growth. Revenue growth of 32.9% demonstrates continued momentum.

Bull Case : VTRS

The strongest argument for VTRS centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.

Bear Case : BFRI

The primary concerns for BFRI are EPS Growth, Market Cap, Debt/Equity.

Bear Case : VTRS

The primary concerns for VTRS are Revenue Growth, Return on Equity, EPS Growth.

Key Dynamics to Monitor

BFRI profiles as a hypergrowth stock while VTRS is a turnaround play — different risk/reward profiles.

VTRS carries more volatility with a beta of 0.88 — expect wider price swings.

BFRI is growing revenue faster at 32.9% — sustainability is the question.

VTRS generates stronger free cash flow (329M), providing more financial flexibility.

Bottom Line

VTRS scores higher overall (48/100 vs 35/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Biofrontera Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Biofrontera Inc., a biopharmaceutical company, develops and supplies dermatological products for the treatment of skin conditions in the United States. The company is headquartered in Woburn, Massachusetts.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?